Leerink Swann Initiates Coverage on Crinetics Pharmaceuticals (CRNX)

Investment analysts at Leerink Swann initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) in a research note issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.

Several other equities analysts also recently commented on CRNX. Piper Jaffray Companies started coverage on shares of Crinetics Pharmaceuticals in a research note on Monday. They set an “overweight” rating for the company. JPMorgan Chase & Co. started coverage on shares of Crinetics Pharmaceuticals in a research note on Monday. They set a “neutral” rating for the company.

Shares of Crinetics Pharmaceuticals opened at $30.68 on Monday, MarketBeat.com reports. Crinetics Pharmaceuticals has a 12 month low of $19.23 and a 12 month high of $32.79.

In related news, Director Life Sciences Maste Perceptive purchased 400,000 shares of the firm’s stock in a transaction that occurred on Friday, July 20th. The stock was bought at an average cost of $17.00 per share, with a total value of $6,800,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alan Seth Krasner purchased 2,000 shares of the firm’s stock in a transaction that occurred on Friday, July 20th. The stock was bought at an average cost of $17.00 per share, with a total value of $34,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 755,180 shares of company stock valued at $13,410,212.

About Crinetics Pharmaceuticals

There is no company description available for Crinetics Pharmaceuticals Inc

Read More: Should you buy a closed-end mutual fund?

The Fly

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply